Program Purpose
The Society for Immunotherapy of Cancer (SITC) and the World Immunotherapy Council (WIC) are dedicated to advancing cancer immunotherapy and, likewise, the future leaders of the field. This program will provide the opportunity for young scientists and future leaders from throughout the world to interact, fulfilling the World Immunotherapy Council’s mission to facilitate rapid development and global dissemination of cancer immunotherapies through scientific exchange.
The young investigators, each chosen for exemplary work in the field of cancer immunotherapy, will contribute insight and perspectives into present and future issues, challenges, and improvements as cancer immunotherapy is integrated into mainstream cancer treatment. This program and its participants will ultimately highlight worldwide initiatives in cancer immunotherapy and facilitate scientific exchange and networking between today’s and tomorrow’s leaders. Additionally, this forum will provide a unique opportunity to showcase the world’s young, talented scientists and provide an opportunity for knowledge exchange and networking for these selected representatives.
Program Organizers
- Bernard A. Fox, PhD – Earle A. Chiles Research Institute, Providence Cancer Institute
- Tanja de Gruijl, PhD – Amsterdam University Medical Centers
- Barbara Seliger, MD, PhD – Institute of Medical Immunology
Target Audience
The target audience for this program consists of individuals from academic institutions, industry and regulatory agencies, including clinicians, basic and translational researchers, graduate students, post-doctoral fellows, and allied health professionals who wish to learn more about the future of cancer immunotherapy research across the globe.
SITC's World Immunotherapy Council's 4th Young Investigator Symposium is supported in part by grants from Bristol Myers Squibb, Merck & Co., Inc., and Pfizer, Inc.
Program Schedule
|
7:30 a.m.
|
Opening Statement
Organizer
|
|
7:45 a.m.
|
Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer
Zheng Zhu—Chinese American Hematology Oncology Network (CAHON)
|
|
8:02 a.m.
|
Chemokine driven spatially organized tumor immunity fosters long survival
Ziena Abdulrahman, Msc—KWF working society-Dutch Tumor Immunology Meeting (KWF-DTIM)
|
|
8:19 a.m.
|
RevCAR platform as a combinatorial approach for targeting acute myeloid leukemia
Liliana Loureiro —Tumor Immunology Meets Oncology (TIMO)
|
| 8:36 a.m. |
Spontaneous clinical research in immuno-oncology: the reality of the SCITO
Margaret Ottaviano—Società Campana di ImmunoTerapia Oncologica (SCITO)
|
| 8:53 a.m. |
Hyperprogressive disease in cancer patients: the dark side of immuno-checkpoint blockade. Lessons from clinical practice and preclinical models²
Roberto Ferrara—Italian Network for Tumor Biotherapy (NIBIT)
|
|
9:10 a.m.
|
Adjuvant and neoadjuvant immunotherapy for hepatocellular carcinoma
Chiun Hsu—the Taiwanese Oncology Society (TOS)
|
|
9:27 a.m.
|
Differential expression of adhesion molecules defines myeloid cell infiltration in glioblastoma and comprises a therapeutic target
Defne Bayik—Society for Immunotherapy of Cancer (SITC)
|
|
9:44 a.m.
|
CRISPR-Cas9-mediated knockout of PD-1 for tumor-infiltrating lymphocyte-based adoptive T-cell therapy
Chris Chamberlain—Scandinavian Network for Immunotherapy of Cancer (SNIC)
|
|
10:01 a.m.
|
Novel model for evaluation of CD3-redirection combinatorial therapies in the context of a syngeneic tumor model with fully competent immune system
Olesya Chornoguz—Progress in Vaccination Against Cancer (PIVAC)
|
|
10:18 a.m.
|
The clinical utility and safety of Short-course Immune checkpoint inhibitors (ICI) in multiple tumors - A real world multicentric study from India
George Abraham— Immuno-Oncology Society of India (I-OSI)
|
|
10:35 a.m.
|
Break
|
|
10:45 a.m.
|
JUPITER-06: a randomized, double-blind phase III trial of toripalimab in combination with paclitaxel plus cisplatin for advanced or metastatic ESCC
Feng Wang— Chinese Society for Clinical Oncology (CSCO)
|
|
11:02 a.m.
|
Trajectory analysis of single cell RNAseq identifies factors involved in immune escape in squamous cell cancers
Quah Hong Sheng—Singapore Society of Oncology - Cancer Immunotherapy Consortium (SSO-CIC)
|
|
11:19 a.m.
|
Combination of NKT cell immunotherapy and oncolytic vesicular stomatitis virus expressing FAST proteins clears metastatic triple negative breast cancer
Adam Nelson—Canadian Cancer Immunotherapy Consortium (CCIC)
|
|
11:36 a.m.
|
Insights into PD-1 blockade: how the Fc region can modulate the therapeutic activity of monoclonal antibodies targeting PD-1
Julia Moreno-Vicente—Spanish Group of Immuno-Biological Therapeutics in Cancer (GETICA)
|
|
11:53 a.m.
|
Evaluation on tumor selectivity of immune response driven by STA551, an anti-CD137 agonist antibody activated in the presence of extracellular ATP
Ryo Uchikawa— Japanese Association of Cancer Immunology (JACI)
|
|
12:10 p.m.
|
The effects of short chain fatty acids on the phenotype and function of human dendritic cells matured with Toll like receptor ligands
Katarzyna Piadel — Institute for Cancer Vaccines and Immunotherapy (ICVI)
|
|
12:27 p.m.
|
Identification of genes and pathways associated with immune modulatory properties of biglycan in colorectal cancer cells
Karthikeyan Subbarayan – German Society for Immunology (DGfl)
|
|
12:45 p.m.
|
Closing Statement
Organizer
|